Previous 10 | Next 10 |
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch t...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
CORAL GABLES, Fla., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...
Investment Thesis Catalyst Pharmaceuticals ( CPRX ) has had an eventful year. The company has launched a new drug after 5 years in development, faced criticism for its perceived excessive pricing point, lost its exclusivity after the FDA approved a rival treatment, launched a lawsuit against...
Catalyst Pharmaceuticals (NASDAQ: CPRX) , a small-cap rare disease specialist, reported its third-quarter earnings after the bell on Tuesday. Yesterday, the drugmaker's shares closed down by 7.5% on over three times the average daily volume. The stock dipped in response to two key developm...
Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2019 Results Earnings Conference Call November 13, 2019, 08:30 AM ET Company Participants Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Steve Miller - Chief Operating Officer and Chief Scien...
Image source: The Motley Fool. Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Q3 2019 Earnings Call Nov 13, 2019 , 8:30 a.m. ET Operator Continue reading
In response to management announcing mixed third-quarter results and sharing tepid guidance, shares of Catalyst Pharmaceuticals (NASDAQ: CPRX) , a commercial-stage biopharma focused on rare diseases, dropped 12% as of 11:03 a.m. EST on Wednesday. Here are some headline numbers from the quart...
Catalyst Pharmaceuticals (NASDAQ: CPRX ): Q3 GAAP EPS of $0.13 beats by $0.02 . Revenue of $30.9M misses by $2.29M . Shares -8.4% . Press Release More news on: Catalyst Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
- Firdapse ® Launch Momentum Continues with Q3 Net Revenues of $30.9 Million -Third Quarter GAAP Net Income of $13.6 Million -Catalyst Provides Net Revenue Guidance – Approximately $100 Million for FY 2019 and range of $135 Million to $155 Million for FY 2020 ...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...